Arquivos do dia: Fevereiro 10, 2022

Estudo randomizado | Em pacientes de 60 anos de idade ou mais com fratura intracapsular de quadril, a hemiartroplastia cimentada resultou em melhor qualidade de vida e menor risco de fratura periprotética do que a hemiartroplastia não cimentada.

10 Fev, 2022 | 14:03h

Cemented or Uncemented Hemiarthroplasty for Intracapsular Hip Fracture – New England Journal of Medicine

 

Comentário no Twitter

Among patients 60+ with an intracapsular hip fracture, cemented hemiarthroplasty resulted in a modestly better quality of life and a lower risk of periprosthetic fracture than uncemented hemiarthroplasty. https://t.co/BKhd0PzXDr pic.twitter.com/8fqx5HbITN

— NEJM (@NEJM) February 9, 2022

 

---

Revisão | Avanços no tratamento do AVC cardioembólico associado com forame oval patente.

10 Fev, 2022 | 14:01h

Advances in the management of cardioembolic stroke associated with patent foramen ovale – The BMJ

Conteúdos relacionados:

Patent Foramen Ovale (PFO) After Stroke: Meta-analysis suggests the application of a multivariable causal classification system may better distinguish patient subgroups who may benefit from PFO closure from those unlikely to receive benefit.

Management of the Patient With Patent Foramen Ovale in 2021: A Spectrum of Cases

Practice advisory update summary: Patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology – Neurology

---

Diretriz científica AHA | Identificação das melhores práticas para a avaliação e o tratamento do AVC em hospital.

10 Fev, 2022 | 14:00h

Identifying Best Practices to Improve Evaluation and Management of In-Hospital Stroke: A Scientific Statement From the American Heart Association – Stroke

Comunicado de imprensa: Five elements to optimize treatment of in-hospital stroke – American Heart Association

 

Comentário no Twitter

Identifying Best Practices to Improve Evaluation and Management of In-Hospital #Stroke: A Scientific Statement From the American Heart Association #AHAJournals #ISC22 https://t.co/e6zcLMeyBZ @American_Heart @AHAScience pic.twitter.com/eBgLc7OrBK

— Stroke AHA/ASA (@StrokeAHA_ASA) February 9, 2022

 

---

Diretriz de prática clínica para uso de tubos de timpanostomia em crianças.

10 Fev, 2022 | 13:58h

Executive Summary of Clinical Practice Guideline on Tympanostomy Tubes in Children (Update) – Otolaryngology–Head and Neck Surgery

---

M-A | Prevalência da solidão em 113 países.

10 Fev, 2022 | 13:57h

The prevalence of loneliness across 113 countries: systematic review and meta-analysis – The BMJ

Editorial: We need a public health approach to loneliness

Comunicado de imprensa: Problematic levels of loneliness widespread in many countries – BMJ

 

Comentário no Twitter

Our latest paper in @bmj_latest shows that problematic levels of #loneliness is common on a global scale. Well done to the team, especially the talented #PhD student @DanielSurkalim who led this work with @DrMelodyDing. What a great publication. Watch this talent. #endloneliness https://t.co/zhdvE6JKaT

— Dr Robert Eres (@robert_eres) February 10, 2022

 

---

Suécia suspende testagem de rotina para COVID-19 e retira as restrições devido a pandemia – “Somente profissionais da saúde e cuidadores de idosos, além dos mais vulneráveis, serão aptos a fazer teste de PCR gratuito se estiverem sintomáticos, enquanto o restante da população será orientado somente a permanecer em casa se apresentarem sintomas sugestivos de COVID-19.”

10 Fev, 2022 | 13:56h

Sweden ends COVID-19 testing as pandemic restrictions lifted – Associated Press

Conteúdos relacionados:

How Denmark Decided COVID Isn’t a Critical Threat to Society – “The country became the first in the EU to lift all COVID restrictions despite leading the world in per capita infections”.

Covid: Europe set for ‘long period of tranquillity’ in pandemic, says WHO.

As Denmark scraps COVID restrictions, WHO urges caution.

Despite the ongoing spread of Omicron, some European countries have decided to lift Covid-19 restrictions.

---

Um estudo de base populacional no Catar mostrou que infecção prévia fornece proteção robusta contra reinfecção pelas variantes Alfa, Beta e Delta do SARS-CoV-2 (cerca de 90%). No entanto, a proteção contra reinfecção pela variante Ômicron foi menor (em torno de 60%).

10 Fev, 2022 | 13:54h

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection – New England Journal of Medicine

 

Comentário no Twitter

Using a national database in Qatar, investigators found that previous #SARSCoV2 infection provided protection against reinfection that ranged from 85% to 92% for alpha, beta, and delta strains and was approx 60% protective against omicron. #COVID19 https://t.co/SGODYCmkP3 pic.twitter.com/OkgjCbyZBj

— NEJM (@NEJM) February 9, 2022

 

---

Estudo randomizado | Análise final de eficácia e segurança da vacina de dose única da J&J.

10 Fev, 2022 | 13:53h

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S – New England Journal of Medicine

 

Comentário no Twitter

A single injection of the Ad26.COV2.S Covid-19 vaccine showed 56.3% vaccine efficacy beginning 14 days after injection and 52.9% efficacy more than 28 days after injection against moderate to severe–critical #COVID19. #IDTwitter https://t.co/0VhaEUtmwq pic.twitter.com/04QqSyYwNI

— NEJM (@NEJM) February 9, 2022

 

---

Efetividade da vacinação heteróloga com CoronaVac e Pfizer no Brasil.

10 Fev, 2022 | 13:51h

Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil – Nature Medicine

 

Comentário no Twitter

An analysis of data from Brazil in @NatureMedicine shows that vaccine effectiveness against SARS-CoV-2 infection and severe COVID-19 outcomes declines after two doses of CoronaVac but increases after a booster dose of the Pfizer-BioNTech vaccine. https://t.co/UCgy6cJFIP pic.twitter.com/pXvkxZHXvv

— Nature Portfolio (@NaturePortfolio) February 9, 2022

 

---

Estudo randomizado | Tirzepatida subcutânea adicionada a insulina glargina titulada melhora o controle glicêmico de pacientes com diabetes tipo 2.

10 Fev, 2022 | 13:49h

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial – JAMA (gratuito por tempo limitado)

Editorial: Tirzepatide for Patients With Type 2 Diabetes – JAMA

Comentário: SURPASS-5 Data: Tirzepatide Plus Insulin Glargine Improve Glycemic Control in T2D – AJMC

Conteúdos relacionados:

RCT: In patients with Type 2 Diabetes, Tirzepatide is associated with reduced weight, improved glycemic control, and lower risk of hypoglycemia compared to insulin glargine.

RCT: Once-weekly tirzepatide vs. once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes.

RCT: Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2.

RCT: Tirzepatide yielded greater glycated hemoglobin and body weight reductions compared to Semaglutide 1 mg.

---